Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 9
Submit an article Journal homepage
394
Views
8
CrossRef citations to date
0
Altmetric
Letters to the Editor

CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents

Ioannis PapageorgiouDepartment of Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL, USA; ;Center for Pharmacogenetics, College of Pharmacy, University of Florida, Gainesville, FL, USA; View further author information
,
Michael R. LokenHematologics Inc, Seattle, WA, USA; View further author information
,
Lisa Eidenschink BrodersenHematologics Inc, Seattle, WA, USA; View further author information
,
Mohammed GbadamosiDepartment of Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL, USA; ;Center for Pharmacogenetics, College of Pharmacy, University of Florida, Gainesville, FL, USA; View further author information
,
Geoffrey L. UyDivision of Oncology, Washington University, St Louis, MI, USA; View further author information
,
Soheil MeshinchiClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USAView further author information
&
Jatinder K. LambaDepartment of Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL, USA; ;Center for Pharmacogenetics, College of Pharmacy, University of Florida, Gainesville, FL, USA; Correspondence[email protected]
View further author information
 show all
Pages 2287-2290 | Received 29 Nov 2018, Accepted 02 Jan 2019, Published online: 05 Feb 2019

References

  • Bernstein ID. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia. 2000;14:474–475.
  • Bernstein ID. CD33 as a target for selective ablation of acute myeloid leukemia. Clin Lymph. 2002;2:S9–S11.
  • Bernstein ID, Singer JW, Andrews RG, et al. Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. J Clin Invest. 1987;79:1153–1159.
  • Jen EY, Ko CW, Lee JE, et al. FDA approval: Gemtuzumab ozogamicin for the treatment of adults with newly-diagnosed CD33-positive acute myeloid leukemia. Clin Cancer Res. 2018;24:3242–3246.
  • Norsworthy KJ, Ko CW, Lee JE, et al. FDA approval summary: Mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia. Oncologist. 2018;23:1103–1108.
  • Walter RB. Investigational CD33-targeted therapeutics for acute myeloid leukemia. Expert Opin Invest Drugs. 2018;27:339–348.
  • Lamba JK, Chauhan L, Shin M, et al. CD33 splicing polymorphism determines Gemtuzumab Ozogamicin response in de novo acute myeloid leukemia: report from randomized Phase III children's oncology group Trial AAML0531. J Clin Oncol. 2017;35:2674–2682.
  • Lamba JK, Voigt AP, Chauhan L, et al. CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients. Leukemia & Lymphoma. 2018;59:2250–2253.
  • Lamba JK, Pounds S, Cao X, et al. Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study. Leukemia. 2009;23:402–404.
  • Mortland L, Alonzo TA, Walter RB, et al. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. Clin Cancer Res. 2013;19:1620–1627.
  • Schweingruber C, Rufener SC, Zund D, et al. Nonsense-mediated mRNA decay - mechanisms of substrate mRNA recognition and degradation in mammalian cells. Biochim Biophys Acta. 2013;1829:612–623.
  • Kervestin S, Jacobson A. NMD: a multifaceted response to premature translational termination. Nat Rev Mol Cell Biol. 2012;13:700–712.
  • Pereverzev AP, Gurskaya NG, Ermakova GV, et al. Method for quantitative analysis of nonsense-mediated mRNA decay at the single cell level. Sci Rep. 2015;5:7729.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.